FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization
Executive Summary
Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.
You may also be interested in...
House Coronavirus Panel Has Questions For Former FDA Commissioner Hahn On Trump Interference
The request for an interview by the House Select Subcommittee on the Coronavirus Crisis seeks more information on the actions by President Trump and others to influence FDA decisions on HCQ, convalescent plasma, and vaccine decisions.
Former FDA Commissioner Hahn Faces Questions From House On Trump Interference, Other COVID Issues
The request for an interview by the House Select Subcommittee on the Coronavirus Crisis seeks more information on the actions by President Trump and others to influence FDA decisions on HCQ, convalescent plasma, and vaccine decisions.
Email Trove From US FDA Shows Peter Marks As Champion For Plasma Authorization
The emergency use authorization for convalescent plasma in August 2020 on weak data from an expanded access program has largely been viewed as a politically charged decision by the Trump administration. But newly revealed emails from the run up to the decision indicate Center for Biologics Evaluation and Research Director Peter Marks backed the plan.